Merck and Inbrain Neuroelectronics collaborate on graphene-based bioelectronic therapy technology [13-07-2021]
Major pharma company Merck has announced a collaboration agreement with Innervia Bioelectronics, a start-up and subsidiary of Inbrain Neuroelectronics S.L., Barcelona, Spain. The aim of the collaboration is to co-develop the next generation of graphene-based bioelectronic vagus nerve therapies targeting severe chronic diseases within the therapeutic areas addressed by Merck.
Related News
Nano-sized vesicles with ACE2 receptor could prevent, treat infection from current and future strains of SARS-CoV-2 [20-01-2022]
Nanobiotechnology, Nanomedicine
Emberion raises 6M euros for its infrared imaging business [18-01-2022]
Grapheal wins prestigious CES 2022 Innovation Award [18-01-2022]
Graphene biosensors outcompete ELISA and Simoa for point-of-care diagnostics [12-01-2022]
Nanobiotechnology, Nanosensors & Nanodevices, Graphene
New graphene-based neural probes improve detection of epileptic brain signals [11-01-2022]
Nanomedicine, Graphene

© Phantoms Foundation 2021